Literature DB >> 8855979

Clonal and functional analysis for the augmentation of tumour-infiltrating lymphocytes by interleukin 4.

T Tsunoda1, H Tanimura, H Yamaue, M Iwahashi, M Tani, K Noguchi, T Hotta, S Mizobata, K Arii.   

Abstract

In the adoptive immunotherapy for cancer, the amounts of induced effector cells play a major role in improving therapeutic efficacy. We have already demonstrated that interleukin 4 (IL-4) augments proliferation of tumour-infiltrating lymphocytes (TILs) without altering the cytotoxic activity against autologous tumour cells. The present study is designed to investigate how IL-4 augments TILs by using established TIL clones in terms of IL-2/IL-2 receptor system. CD4+, CD8+ and CD4+ CD8+ (double positive) TIL clones were established from cancer patients. At clonal level, IL-4 augmented the proliferation of IL-2-activated TIL clones irrespective of phenotypes. In order to clarify the mechanism of IL-4 at clonal level, the blocking assay by anti-IL-2 receptor alpha and beta chain and binding assay of IL-2 on the cell surface and the measurement of the internalisation of IL-2 in the cell were performed. It was clarified that IL-4 up-regulated the IL-2 receptor and then augmented the action of IL-2 molecule on the cell surface stimulated by IL-4. Furthermore, binding IL-2 internalised rapidly into the cells. Thus, it is suggested that signal transduction is augmented and proliferation of TILs is enhanced by IL-4 via the action of IL-2/IL-2 receptor system.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8855979      PMCID: PMC2077114          DOI: 10.1038/bjc.1996.494

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  39 in total

1.  In vivo thymocyte maturation. BUdR labeling of cycling thymocytes and phenotypic analysis of their progeny support the single lineage model.

Authors:  C Penit
Journal:  J Immunol       Date:  1986-10-01       Impact factor: 5.422

2.  The effects of IL-4 on human natural killer cells. A potent regulator of IL-2 activation and proliferation.

Authors:  A Nagler; L L Lanier; J H Phillips
Journal:  J Immunol       Date:  1988-10-01       Impact factor: 5.422

Review 3.  The role of IL4 and IL5: characterization of a distinct helper T cell subset that makes IL4 and IL5 (Th2) and requires priming before induction of lymphokine secretion.

Authors:  S L Swain; D T McKenzie; R W Dutton; S L Tonkonogy; M English
Journal:  Immunol Rev       Date:  1988-02       Impact factor: 12.988

4.  The IL-2 receptor beta chain (p70): role in mediating signals for LAK, NK, and proliferative activities.

Authors:  J P Siegel; M Sharon; P L Smith; W J Leonard
Journal:  Science       Date:  1987-10-02       Impact factor: 47.728

5.  An autoreactive T cell clone generated in the autologous mixed lymphocyte reaction in a patient with gastric carcinoma.

Authors:  M Iwahashi; H Tanimura; H Yamaue; T Tsunoda; M Tani; K Noguchi; S Mizobata; T Hotta; M Tamai
Journal:  J Clin Lab Immunol       Date:  1993

Review 6.  B-cell stimulatory factor-1/interleukin 4.

Authors:  W E Paul; J Ohara
Journal:  Annu Rev Immunol       Date:  1987       Impact factor: 28.527

7.  Recombinant interleukin 4 promotes the growth of human T cells.

Authors:  H Spits; H Yssel; Y Takebe; N Arai; T Yokota; F Lee; K Arai; J Banchereau; J E de Vries
Journal:  J Immunol       Date:  1987-08-15       Impact factor: 5.422

8.  Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study.

Authors:  S L Topalian; D Solomon; F P Avis; A E Chang; D L Freerksen; W M Linehan; M T Lotze; C N Robertson; C A Seipp; P Simon
Journal:  J Clin Oncol       Date:  1988-05       Impact factor: 44.544

9.  Internalization of interleukin 2 is mediated by the beta chain of the high-affinity interleukin 2 receptor.

Authors:  R J Robb; W C Greene
Journal:  J Exp Med       Date:  1987-04-01       Impact factor: 14.307

10.  Interleukin 4 (B cell stimulatory factor 1) can mediate the induction of lymphokine-activated killer cell activity directed against fresh tumor cells.

Authors:  J J Mulé; C A Smith; S A Rosenberg
Journal:  J Exp Med       Date:  1987-09-01       Impact factor: 14.307

View more
  3 in total

1.  Enhancement of tumor cell susceptibility to tumor-infiltrating lymphocytes by cisplatin.

Authors:  K Noguchi; H Tanimura; H Yamaue; M Iwahashi; T Tsunoda; M Tani; M Tamai; T Hotta; S Mizobata; K Arii
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

2.  Characterization of human cellular immune responses to novel Mycobacterium tuberculosis antigens encoded by genomic regions absent in Mycobacterium bovis BCG.

Authors:  R Al-Attiyah; A S Mustafa
Journal:  Infect Immun       Date:  2008-06-23       Impact factor: 3.441

3.  Potential immunotherapeutic role of interleukin-2 and interleukin-12 combination in patients with hepatocellular carcinoma.

Authors:  Abdulwahab Ali Gabeen; Fatma Farag Abdel-Hamid; Motawa Eisa El-Houseini; Shadia Abdel-Hamid Fathy
Journal:  J Hepatocell Carcinoma       Date:  2014-06-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.